Intuitive Ventures

Intuitive Ventures focuses on early-stage start-ups and takes a long-term outlook to support companies to reach their major milestones. Through its inaugural $100 million funds and with leadership combining decades of investing and operational experience, the team cultivates strategic resources to drive financial returns and accelerate the future of minimally invasive care. Intuitive Ventures has already started deploying capital and is actively building its portfolio.

Jotthe Kannappan

Senior Associate

Oliver Keown

Founder and Managing Director

5 past transactions

Dasera

Series A in 2023
Dasera is a Data Security Posture Management (DSPM) platform that automates security and governance controls across structured and unstructured data in your cloud, on-prem, and hybrid environments. It empowers organizations to manage risk across their entire data lifecycle, from creation to deletion, ensuring compliance with evolving data privacy regulations.

Optellum

Series A in 2022
Optellum develops an imaging biomarker for smart lung cancer detection. Optellum’s vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way. They do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets. Their first suite of products targets management of patients at high risk of developing lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment. Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision lab. Between us, they have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. They are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors. They are building up their product development team – join their fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups (e.g. Mirada Solutions – acquired by Siemens).

Flywheel.io

Series C in 2021
Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Endogenex

Venture Round in 2021
Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.

KelaHealth

Seed Round in 2020
KelaHealth Surgical Intelligence Platform delivers patient-specific predictive insights and recommended interventions at key decision points to improve surgical care quality and clinical operations. It is creating a learning ecosystem to improve surgical care outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.